DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.

Author(s): Shearer J, Shanahan M, Darke S, Rodgers C, van Beek I, McKetin R, Mattick RP

Affiliation(s): Peninsula Medical School, University of Exeter, Exeter, United Kingdom. shearerjames7@gmail.com

Publication date & source: 2010-05, Drug Alcohol Rev., 29(3):235-42.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

INTRODUCTION AND AIMS: To examine the cost-effectiveness of modafinil (200 mg daily) plus counselling compared with placebo for the treatment of psychostimulant dependence. DESIGN AND METHODS: Cost and outcome data were collected alongside two randomised controlled trials of modafinil 200 mg daily over 10 weeks for methamphetamine (n = 74) and cocaine dependence (n = 8), respectively. Incremental cost-effectiveness ratios representing the additional costs to achieve a given outcome were calculated for both the change in the number of stimulant-free days and quality-adjusted life years 12 weeks post-treatment. RESULTS: The incremental cost-effectiveness ratio indicated that it would cost an additional $AUD79 to achieve an extra stimulant-free day with modafinil compared with placebo. This result was not statistically significant, but appeared to be a robust estimate after sensitivity analysis. Counselling, whether received within program or from other services, improved the cost-effectiveness of modafinil relative to placebo. DISCUSSION AND CONCLUSIONS: Strategies to improve the uptake of counselling are recommended as cost-effective.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017